New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For CLDX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 30, 2014
16:14 EDTCLDXCelldex glembatumumab vedotin Phase 1/2 studies published
Subscribe for More Information
September 26, 2014
10:01 EDTCLDXOn The Fly: Analyst Initiation Summary
Subscribe for More Information
06:35 EDTCLDXCelldex initiated with an Outperform at Cowen
Subscribe for More Information
September 25, 2014
08:07 EDTCLDXCelldex initiates CDX-301 pilot study
Celldex Therapeutics announced the initiation of a pilot study of CDX-301 for the mobilization and transplantation of allogeneic hematopoietic stem cells in patients with hematological malignancies undergoing hematopoietic stem cell transplantation, or HSCT. The study will explore the utility of CDX-301, also known as FMS-like tyrosine kinase-3 ligand or Flt3L, alone and in combination with Mozobil and is supported by preclinical data demonstrating that the combination of CDX-301 and Mozobil increased hematopoietic stem cell mobilization and improved transplantation of mobilized cells. The open-label, pilot study will enroll up to 36 participants, or 18 recipient/donor pairs, ages 18 to 65 across two sequentially enrolled cohorts in approximately 10 clinical trial sites in the United States. Study participants include patients with specified hematologic malignancies and Human Leukocyte Antigen, or HLA, sibling-matched healthy volunteers. The primary objective is to assess the safety and tolerability of CDX-301 when given with or without Mozobil. Secondary endpoints will evaluate the adequacy of the resultant grafts as determined by CD34+ yield, the cellular composition of the resultant grafts, and the safety and effectiveness of the resulting grafts across multiple measures.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use